Skip to main content

Table 6 Clinical and neuropathological criteria

From: A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer’s disease

Study Sample Database Neuropathological criteria Autopsy Dementia criteria
McKeith et al ., 1992 [[20]] AD 37 Newcastle, UK AD: plaque/tangle quantification, H + E, CFV, Loyez, Palmgren. All DLB: proposed consensus (1992)
SDLT 21
LB: H + E, pholxine, erythrosin
Ballard et al ., 1996 [[17]] AD 53 West Midlands and Bristol, UK   0 AD: NINCDS/ADRDA (1984)
SDLT 7 DLB: McKeith, operational criteria for senile dementia of Lewy body type (1992)
VaD 14
Ballard et al., 1998 [[21]] AD 30 Newcastle General Hospital, UK AD: CERAD, plaque - Braunmuhl stain, tangle - modified Palmgren 19 AD: NINCDS/ADRDA (1984)
DLB 42 DLB: McKeith, operational criteria for senile dementia of Lewy body type (1992)
LB: consensus criteria (1996), ubiquitin, anti-tau2, anti-Alz50, anti-AT8 to detect and distinguish cortical LB
Olichney et a l., 1998 [[3]] AD 148 Cohort from: AD: CERAD, ADRC All AD: NINCDS/ADRDA (1984),
LBV 40 Univeristy of California, San Diego Alzheimer’s Disease Research Center, USA; LB: ubiquitin, H + E (brainstem, cerebral cortex) DSM-III for dementia
CERAD centers, multinational
Heyman et al ., 1999 [[18]] AD 74 Subjects with premortem diagnosis of probable and possible AD from 24 centers participating in CERAD, 1986 to 1995, USA AD: CERAD All AD: NINCDS/ADRDA (1984)
AD/LBV 27 LB: consensus criteria (1996), modified (brainstem, limbic/transitional and noecortical).
Lopez et al ., 2000 [[22]] AD 98 University of Pittsburg 1983 to 1998, USA AD: CERAD, NIA-RI All AD: NINCDS/ADRDA (1984)
AD/DLB 44 LB: H + E, ubiqutin (SN, neocortex, limbic areas) DLB: consensus criteria (1996)
Stern et al . 2001 [[23]] AD 32 From cohort of 236 patients with probable AD AD: CERAD All AD: NINCDS/ADRDA (1984)
LBV 19 LB: semi quantitative ubiquitin (SN, hippocampus, cingulate gyrus, insula cortex)
Recruited:
Columbia University College, New York, USA
Johns Hopkins University, Baltimore, USA
Massachusetts General Hospital, Boston, USA
Ballard et al ., 2001 [[24]] AD 101 Cohort of 227 patients AD: CERAD, plaque - Braunmuhl stain, tangle - modified Palmgren 50 AD: NINCDS/ADRDA (1984)
DLB 64 Institute of the Health of the Elderly (IHE), Newcastle, UK DLB: consensus criteria (1996)
VaD 38 LB: consensus criteria (1996), ubiquitin, anti-tau2, anti-Alz50, anti-AT8 to detect and distinguish cortical LB
Helmes et al ., 2003 [[25]] AD 15 University of Western Ontario Dementia Study, Canada No criteria are referred to. Only referred to LB staining methods (Bielschovsky, anti-ubiquitin, anti-synuclein). All Not specified.
AD/DLB 8
DLB 7
Johnson et al ., 2005 [[26]] AD 66 Washington University, from 1979, USA AD: NIA-RI quantification of diffuse and neuritic depositions in 10 cortical regions All AD: NINCDS/ADRDA (1984)
AD/DLB 57 DLB: consensus criteria (1996) or McKeith, operational criteria for senile dementia of Lewy body type (1992)
DLB 9 LB: synuclein
Kraybill et al ., 2005 [[15]] AD 48 Cohort from University of Washington/Group Health Cooperative Alzheimer’s Disease Patient Registry, USA AD: CERAD, Braak stages > IV All AD: NINCDS/ADRDA (1984)
AD/LBP 65 LB/AD: AD + synuclein (amygdala, SN) DLB: missing criteria because study was started before the consensus criteria for DLB was established.
LBP 22
LB: Braak stages < III, synuclein (amygdala, SN)
Stavitsky et a l., 2006 [[19]] AD 55 Cohort of the Predictors Study, 1997: AD: CERAD 12 AD: NINCDS/ADRDA (1984)
DLB 28 LB: semi quantitative ubiquitin (hippocampus, cingulate gyrus, insula cortex) DLB: consensus criteria (1996)
Columbia University
Johns Hopkins University,
Massachusetts General Hospital, USA
Williams et al ., 2006 [[27]] AD 252 Cohort from Washington University, USA AD: NIA-RI quantification of diffuse and neuritic depositions in 10 cortical regions All AD: NINCDS/ADRDA (1984)
DLB 63 DLB: consensus criteria (1996)
LB: synuclein
Hamilton et al ., 2008 [[28]] AD 44 University of California, Alzheimer’s disease center San Diego, 1985 to 2002, USA AD: modified Braak staging, NIA-RI (1997) and CERAD (1991) All AD: NIA-RI and CERAD (1988)
DLB 22 DLB: consensus criteria (1996)
LB: H + E, ubiquitin (1996) synuclein (2005)
Hanyu et al ., 2009 [[29]] AD 111 Memory Clinic of Tokyo Medical University, 2000 to 2006, Japan   0 AD: NINCDS/ADRDA (1984)
DLB 56 DLB: consensus criteria (1996)
Nelson et al ., 2009 [[16]] AD 107 National Alzheimer’s Coordinating Center (NACC) Registry - 31 AD centers in USA, AD: NIA-RI All AD: CERAD (1988)
AD/DLB 27 University of Kentucky Alzheimer’s Disease Center, USA LB: Braak staging and CERAD DLB: consensus criteria (1996)
DLB 9
Wood et a l., 2012 [[30]] AD 16 Newcastle University, UK   0 AD: NINCDS/ADRDA (1984)
DLB 12 DLB: consensus criteria (2005) or (1996)
Walker et al . 2012 [[31]] AD 100 40 European sites 123I-FTP-SPECT as verifying method 0 AD: NINCDS/ADRDA (1984)
DLB 58 DLB: consensus criteria (1996)
  1. AD, Alzheimer’s disease; ADRC, Alzheimer’s Disease Research Center; CERAD, The Consortium to Establish a Registry for Alzheimer's Disease; CFV, creasyl fast violet; DLB, dementia with Lewy bodies; H + E, hematoxylin and eosin staining; I-FTP-SPECT, ioflupane single-photon emission computed tomography; LB Lewy body; LBV, Lewy body variant; LBP, Lewy body pathology; NIA-RI, National Institute on Aging-Reagan; NINCDS/ADRDA, National Institute of Neurological and Communication Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association; SDLT, senile dementia of Lewy body type; SN, substantia nigra.